Nah man, oto-313 for tinnitus will be phase 1/2. They have already demonstrated safety. I’m waiting to hear if @David from BTA saw there presentation from ARO-2019
Otonomy is a strong company with plenty of cash. Much talk is on Frequency but Otonomy have a strong pipeline of products for various ear disorders in testing.
Otonomy will be the ONLY company with 3 indications (HL, T & V) in pipeline in 2019 in trials. Any idea when a Q&A with them @Markku, 2019 will be an interesting year for them and us.
I’ve tried emailing 2 of the address’s but they fail to send, I will do a bit of digging & get back to you. 3 drugs starting phase 1/2 this year with a lot of questions we can ask!!
I’ve been intouch with ATEOS, he thinks they may be aiming for both acute AND chronic, that I’m sure will spark many members interest, as well as the hidden hearing loss synapse repair trial. I’ll see what I can find out Markku & find a contact
Comments on Profile Post by Paulmanlike